Page 154 - Read Online

Page 22 Spiliopoulou et al. Cancer Drug Resist 2024;7:2 https://dx.doi.org/10.20517/cdr.2023.46

Dermatol 2020;182:1214-20. DOI PubMed
+
+
106. Pircher A, Gamerith G, Amann A, et al. Neoadjuvant chemo-immunotherapy modifies CD4 CD25 regulatory T cells (Treg) in non-
small cell lung cancer (NSCLC) patients. Lung Cancer 2014;85:81-7. DOI
+
107. Koh J, Hur JY, Lee KY, et al. Regulatory (FoxP3 ) T cells and TGF-β predict the response to anti-PD-1 immunotherapy in patients
with non-small cell lung cancer. Sci Rep 2020;10:18994. DOI PubMed PMC
108. Kumagai S, Togashi Y, Kamada T, et al. The PD-1 expression balance between effector and regulatory T cells predicts the clinical
efficacy of PD-1 blockade therapies. Nat Immunol 2020;21:1346-58. DOI
109. Santagata S, Trotta AM, Rea G, et al. Abstract 6675: basal NK activity and early Tregs inhibition predicts nivolumab responsiveness
in metastatic renal cancer patients (REVOLUTION) trial. Cancer Res 2020;80:6675. DOI
110. Di Giacomo AM, Santangelo F, Amato G, et al. First-in-human (FIH) phase I study of the highly selective phosphoinositide 3-kinase
inhibitor delta (PI3Kδ) inhibitor IOA-244 in patients with advanced cancer: safety, activity, pharmacokinetic (PK), and
pharmacodynamic (PD) results. J Clin Oncol 2022;40:3107. DOI
+
111. Kamphorst AO, Pillai RN, Yang S, et al. Proliferation of PD-1 CD8 T cells in peripheral blood after PD-1-targeted therapy in lung
cancer patients. Proc Natl Acad Sci U S A 2017;114:4993-8. DOI PubMed PMC
112. De Simone M, Arrigoni A, Rossetti G, et al. Transcriptional landscape of human tissue lymphocytes unveils uniqueness of tumor-
infiltrating T regulatory cells. Immunity 2016;45:1135-47. DOI PubMed PMC
113. Plitas G, Konopacki C, Wu K, et al. Regulatory T cells exhibit distinct features in human breast cancer. Immunity 2016;45:1122-34.
DOI PubMed PMC
+
+
114. Barsheshet Y, Wildbaum G, Levy E, et al. CCR8 FOXp3 T cells as master drivers of immune regulation. Proc Natl Acad Sci U S
reg
A 2017;114:6086-91. DOI PubMed PMC
115. Zdanov S, Mandapathil M, Abu Eid R, et al. Mutant KRAS conversion of conventional T cells into regulatory T cells. Cancer
Immunol Res 2016;4:354-65. DOI PubMed PMC
116. Kalvala A, Wallet P, Yang L, et al. Phenotypic switching of naïve T cells to immune-suppressive Treg-like cells by mutant KRAS. J
Clin Med 2019;8:1726. DOI
117. Kumagai S, Koyama S, Itahashi K, et al. Lactic acid promotes PD-1 expression in regulatory T cells in highly glycolytic tumor
microenvironments. Cancer Cell 2022;40:201-18.e9. DOI PubMed
118. Wang J, Ke XY. The four types of Tregs in malignant lymphomas. J Hematol Oncol 2011;4:50. DOI PubMed PMC
119. Peng F, Qin Y, Mu S, Li J, Ai L, Hu Y. Prognostic role of regulatory T cells in lymphoma: a systematic review and meta-analysis. J
Cancer Res Clin Oncol 2020;146:3123-35. DOI PubMed
120. Nixon AB, Schalper KA, Jacobs I, Potluri S, Wang IM, Fleener C. Peripheral immune-based biomarkers in cancer immunotherapy:
can we realize their predictive potential? J Immunother Cancer 2019;7:325. DOI PubMed PMC
121. Ding P, Wen L, Tong F, Zhang R, Huang Y, Dong X. Mechanism underlying the immune checkpoint inhibitor-induced hyper-
progressive state of cancer. Cancer Drug Resist 2022;5:147-64. DOI PubMed PMC
122. Zang H, Peng J, Zheng H, Fan S. Hyperprogression after immune-checkpoint inhibitor treatment: characteristics and hypotheses.
Front Oncol 2020;10:515. DOI PubMed PMC
+
123. Kamada T, Togashi Y, Tay C, et al. PD-1 regulatory T cells amplified by PD-1 blockade promote hyperprogression of cancer. Proc
Natl Acad Sci U S A 2019;116:9999-10008. DOI PubMed PMC
124. Woods DM, Ramakrishnan R, Laino AS, et al. Decreased suppression and increased phosphorylated STAT3 in regulatory T cells are
associated with benefit from adjuvant PD-1 blockade in resected metastatic melanoma. Clin Cancer Res 2018;24:6236-47. DOI
PubMed PMC
125. Gadi D, Griffith A, Tyekucheva S, et al. A T cell inflammatory phenotype is associated with autoimmune toxicity of the PI3K
inhibitor duvelisib in chronic lymphocytic leukemia. Leukemia 2022;36:723-32. DOI PubMed PMC
126. Weidner AS, Panarelli NC, Geyer JT, et al. Idelalisib-associated colitis: histologic findings in 14 patients. Am J Surg Pathol
2015;39:1661-7. DOI
127. Manna A, Kellett T, Aulakh S, et al. Targeting CD38 is lethal to Breg-like chronic lymphocytic leukemia cells and Tregs, but restores
+
CD8 T-cell responses. Blood Adv 2020;4:2143-57. DOI PubMed PMC
hi + lo
128. Jitschin R, Braun M, Büttner M, et al. CLL-cells induce IDO CD14 HLA-DR myeloid-derived suppressor cells that inhibit T-cell
responses and promote T Regs . Blood 2014;124:750-60. DOI
129. Mékinian A, Quinquenel A, Belkacem KA, et al. Immuno-regulatory malignant B cells contribute to chronic lymphocytic leukemia
progression. Cancer Gene Ther 2023;30:1018-28. DOI PubMed PMC
130. Massa M, Rosti V, Campanelli R, Fois G, Barosi G. Rapid and long-lasting decrease of T-regulatory cells in patients with
myelofibrosis treated with ruxolitinib. Leukemia 2014;28:449-51. DOI PubMed
131. Keohane C, Kordasti S, Seidl T, et al. JAK inhibition induces silencing of T Helper cytokine secretion and a profound reduction in T
regulatory cells. Br J Haematol 2015;171:60-73. DOI
132. Arce Vargas F, Furness AJS, Litchfield K, et al. Fc effector function contributes to the activity of human anti-CTLA-4 antibodies.
Cancer Cell 2018;33:649-63.e4. DOI
133. Galvez-Cancino F, Simpson AP, Costoya C, et al. Fcγ receptors and immunomodulatory antibodies in cancer. Nat Rev Cancer
2024;24:51-71. DOI
134. Chen CM, Wu WB, Chen JF, Chen Y. Characterization of the in vitro metabolites of idelalisib in liver microsomes and interspecies